“In this double-blind, randomized, placebo-controlled, dose-ranging, multicenter Phase 2 trial, Astrum demonstrated fast, reliable responsiveness and a highly proactive approach. Their solution-oriented support, including strong data management input during CRF development and close collaboration on regulatory responses, was instrumental to the smooth progress of the study.”
